Improving strategies for the diagnosis of cardiac amyloidosis

References

• Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014;21:221-4
   PubMed Web of Science ®Google Scholar
• Bellavia D, Pellikka PA, Dispenzieri A, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging 2012;13:680-9
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-95
   PubMed Web of Science ®Google Scholar
• Kristen AV, Scherer K, Buss S, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging 2014;7:502-10
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Dispenzieri A, Gertz MA, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 2015;90:181-6
   PubMed Web of Science ®Google Scholar
• Peled Y, Gramlich M, Yoskovitz G, et al. Titin mutation in familial restrictive cardiomyopathy. Int J Cardiol 2014;171:24-30
   Google Scholar
• Kourelis TV, Kumar SK, Go RS, et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol 2014;89:1051-4
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013;31:4319-24
   PubMed Web of Science ®Google Scholar
• Perfetti V, Palladini G, Casarini S, et al. The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 2012;119:144-50
   PubMed Web of Science ®Google Scholar
• Taxiarchis V, Kourelis DS, Jason D. Theis, marina ramirez-alvarado, paul kurtin, morie gertz, stephen zeldenrust, ahmet dogan and angela dispenzieri. clarifying immunoglobulin gene family usage. In AL amyloidosis by mass spectrometry of amyloid. ISA annual meeting. Indianapolis, IN; 2014
   Google Scholar
• Warsame R, Kumar SK, Gertz MA, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J 2015;5:e310
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Zhang Y, Martinez C, et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001;98:714-20
   PubMed Web of Science ®Google Scholar
• Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003;101:3801-8
   PubMed Web of Science ®Google Scholar
• Perfetti V, Casarini S, Palladini G, et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 2002;100:948-53
   PubMed Web of Science ®Google Scholar
• Wilson MR, Yerbury JJ, Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mol Biosyst 2008;4:42-52
   PubMed Web of Science ®Google Scholar
• Shin JT, Ward JE, Collins PA, et al. Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid 2012;19:191-6
   PubMed Web of Science ®Google Scholar
• Diomede L, Rognoni P, Lavatelli F, et al. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood 2014;123:3543-52
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594-7
   PubMed Web of Science ®Google Scholar
• Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10
   PubMed Web of Science ®Google Scholar
• Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 2010;107:4188-93
   PubMed Web of Science ®Google Scholar
• Dubrey S, Mendes L, Skinner M, et al. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996;125:481-4
   PubMed Web of Science ®Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107:3854-8
   PubMed Web of Science ®Google Scholar
• Tsai SB, Seldin DC, Wu H, et al. Myocardial infarction with “clean coronaries” caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid 2011;18:160-4
   Web of Science ®Google Scholar
• Dorbala S, Vangala D, Bruyere JJr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail 2014;2:358-67
   PubMed Web of Science ®Google Scholar
• Tanaka K, Essick EE, Doros G, et al. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc 2013;2:e005868
   PubMed Web of Science ®Google Scholar
• Biolo A, Ramamurthy S, Connors LH, et al. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition. Circ Heart Fail 2008;1:249-57
   PubMed Web of Science ®Google Scholar
• Boldrini M, Salinaro F, Mussinelli R, et al. Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 2013;18:327-35
   PubMed Web of Science ®Google Scholar
• Goldsmith YB, Liu J, Chou J, et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol 2009;104:990-4
   PubMed Web of Science ®Google Scholar
• Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J 2015;36:1098-105
   PubMed Web of Science ®Google Scholar
• Al-Zahrani GB, Bellavia D, Pellikka PA, et al. Doppler myocardial imaging compared to standard two-dimensional and Doppler echocardiography for assessment of diastolic function in patients with systemic amyloidosis. J Am Soc Echocardiogr 2009;22:290-8
   Web of Science ®Google Scholar
• Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry 2013;52:1913-26
   PubMed Web of Science ®Google Scholar
• Reixach N, Deechongkit S, Jiang X, et al. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA 2004;101:2817-22
   PubMed Web of Science ®Google Scholar
• Bourgault S, Choi S, Buxbaum JN, et al. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 2011;410:707-13
   PubMed Web of Science ®Google Scholar
• Azevedo EP, Guimaraes-Costa AB, Torezani GS, et al. Amyloid fibrils trigger the release of neutrophil extracellular traps (NETs), causing fibril fragmentation by NET-associated elastase. J Biol Chem 2012;287:37206-18
   PubMedGoogle Scholar
• Sidorova TN, Mace LC, Wells KS, et al. Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples. J Histochem Cytochem 2014;62:479-87
   Google Scholar
• Sousa MM, Cardoso I, Fernandes R, et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 2001;159:1993-2000
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113-22
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Tagoe C, Gallo G, et al. Why are some amyloidoses systemic? Does hepatic “chaperoning at a distance” prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? Faseb J 2012;26:2283-93
   PubMed Web of Science ®Google Scholar
• Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008;40:232-9
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73
   PubMed Web of Science ®Google Scholar
• Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med 2015;372:21-9
   PubMed Web of Science ®Google Scholar
• Magalhaes J, Saraiva MJ. Clusterin overexpression and its possible protective role in transthyretin deposition in familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol 2011;70:1097-106
   PubMed Web of Science ®Google Scholar
• Greene MJ, Klimtchuk ES, Seldin DC, et al. Cooperative stabilization of transthyretin by clusterin and diflunisal. Biochemistry 2015;54:268-78
   Google Scholar
• Greene MJ, Sam F, Soo Hoo PT, et al. Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol 2011;178:61-8
   PubMed Web of Science ®Google Scholar
• Sorgjerd K, Ghafouri B, Jonsson BH, et al. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis. J Mol Biol 2006;356:469-82
   Google Scholar
• Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008;15:40-8
   PubMed Web of Science ®Google Scholar
• Goncalves I, Alves CH, Quintela T, et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem 2008;317:137-42
   PubMed Web of Science ®Google Scholar
• Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006;15:287-90
   PubMed Web of Science ®Google Scholar
• Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-7
   PubMed Web of Science ®Google Scholar
• Ariyarajah V, Steiner I, Hajkova P, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009;113:132-7
   Google Scholar
• Millucci L, Paccagnini E, Ghezzi L, et al. Different factors affecting human ANP amyloid aggregation and their implications in congestive heart failure. PLoS ONE 2011;6:e21870
   Google Scholar
• Millucci L, Ghezzi L, Bernardini G, et al. Prevalence of isolated atrial amyloidosis in young patients affected by congestive heart failure. ScientificWorldJournal 2012;2012:293863
   Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013;121:5124-30
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7
   PubMed Web of Science ®Google Scholar
• Pinney JH, Whelan CJ, Petrie A, et al. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2013;2:e000098
   PubMed Web of Science ®Google Scholar
• Gutierrez PS, Fernandes F, Mady C, et al. Clinical, electrocardiographic and echocardiographic findings in significant cardiac amyloidosis detected only at necropsy: comparison with cases diagnosed in life. Arq Bras Cardiol 2008;90:191-6
   Google Scholar
• Koivuniemi R, Paimela L, Suomalainen R, et al. Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 2008;15:262-8
   PubMed Web of Science ®Google Scholar
• Takigawa M, Hashimura K, Ishibashi-Ueda H, et al. Annual electrocardiograms consistent with silent progression of cardiac involvement in sporadic familial amyloid polyneuropathy: a case report. Intern Med 2010;49:139-44
   Google Scholar
• Finocchiaro G, Merlo M, Pinamonti B, et al. Long term survival in patients with cardiac amyloidosis. Prevalence and characterisation during follow-up. Heart Lung Circ 2013;22:647-54
   Google Scholar
• Singh V, Fishman JE, Alfonso CE. Primary systemic amyloidosis presenting as constrictive pericarditis. Cardiology 2011;118:251-5
   Google Scholar
• Kristen AV, Schnabel PA, Winter B, et al. High prevalence of amyloid in 150 surgically removed heart valves–a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol 2010;19:228-35
   Google Scholar
• Lobato L, Beirao I, Silva M, et al. End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors. Amyloid 2004;11:27-37
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 2013;34:520-8
   PubMed Web of Science ®Google Scholar
• Wang AK, Fealey RD, Gehrking TL, et al. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc 2008;83:1226-30
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol 2013;22:189-94
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5
   PubMed Web of Science ®Google Scholar
• Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263:294-301
   PubMed Web of Science ®Google Scholar
• Damy T, Deux JF, Moutereau S, et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Amyloid 2013;20:212-20
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9
   PubMed Web of Science ®Google Scholar
• Cheng Z, Zhu K, Tian Z, et al. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol 2013;18:157-62
   PubMed Web of Science ®Google Scholar
• Cyrille NB, Goldsmith J, Alvarez J, et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 2014;114:1089-93
   PubMed Web of Science ®Google Scholar
• Namdar M, Steffel J, Jetzer S, et al. Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 2012;109:587-93
   Google Scholar
• Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984;3(1):107-13
   Google Scholar
• Tomas MT, Santa-Clara MH, Monteiro E, et al. Body composition, muscle strength, functional capacity, and physical disability risk in liver transplanted familial amyloidotic polyneuropathy patients. Clin Transplant 2011;25:E406-14
   Google Scholar
• Parrillo JE, Aretz HT, Palacios I, et al. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure. Endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation 1984;69:93-101
   PubMed Web of Science ®Google Scholar
• Pellikka PA, Holmes DRJr, Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med 1988;148:662-6
   PubMedGoogle Scholar
• Bochtler T, Hegenbart U, Kunz C, et al. Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. J Clin Oncol 2015;33:1371-8
   PubMed Web of Science ®Google Scholar
• Bochtler T, Hegenbart U, Kunz C, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid 2014;21:9-17
   PubMed Web of Science ®Google Scholar
• Fine NM, Arruda-Olson AM, Dispenzieri A, et al. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 2014;113:1723-7
   PubMed Web of Science ®Google Scholar
• Clement CG, Truong LD. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis. Hum Pathol 2014;45:1766-72
   PubMed Web of Science ®Google Scholar
• Vrana JA, Theis JD, Dasari S, et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica 2014;99:1239-47
   PubMed Web of Science ®Google Scholar
• Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian Blue stain for amyloid in cardiac pathology. J Clin Pathol 1976;29:22-6
   PubMed Web of Science ®Google Scholar
• Gilbertson JA, Theis JD, Vrana JA, et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol 2015;68:314-17
   PubMed Web of Science ®Google Scholar
• Satoskar AA, Efebera Y, Hasan A, et al. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol 2011;35:1685-90
   PubMed Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-9
   PubMed Web of Science ®Google Scholar
• Theis JD, Dasari S, Vrana JA, et al. Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. J Mass Spectrom 2013;48:1067-77
   PubMed Web of Science ®Google Scholar
• Jason DT, Julie AV, Oana MM, et al. Proteome of amyloidosis: Mayo Clinic Experience In 4139 Cases. Blood 2013;122(21)
   Google Scholar
• Casadonte R, Kriegsmann M, Deininger SO, et al. Imaging mass spectrometry analysis of renal amyloidosis biopsies reveals protein co-localization with amyloid deposits. Anal Bioanal Chem 2015;407(18):5323-31
   Google Scholar
• Dasari S, Theis JD, Vrana JA, et al. Proteomic detection of immunoglobulin light chain variable region peptides from amyloidosis patient biopsies. J Proteome Res 2015;14:1957-67
   PubMed Web of Science ®Google Scholar
• D’Souza A, Theis J, Quint P, et al. Exploring the amyloid proteome in immunoglobulin-derived lymph node amyloidosis using laser microdissection/tandem mass spectrometry. Am J Hematol 2013;88:577-80
   PubMed Web of Science ®Google Scholar
• Linke RP. On typing amyloidosis using immunohistochemistry. Detailed illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 2012;47:61-132
   PubMed Web of Science ®Google Scholar
• Fernandez de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015;125:2239-44
   PubMed Web of Science ®Google Scholar
• Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8
   PubMed Web of Science ®Google Scholar
• Baccouche H, Maunz M, Beck T, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography 2012;29:668-77
   PubMed Web of Science ®Google Scholar
• Sun JP, Stewart WJ, Yang XS, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-15
   PubMed Web of Science ®Google Scholar
• Porciani MC, Lilli A, Perfetto F, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid 2009;16:63-70
   PubMed Web of Science ®Google Scholar
• Bellavia D, Abraham TP, Pellikka PA, et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 2007;20:1194-202
   PubMed Web of Science ®Google Scholar
• Lindqvist P, Olofsson BO, Backman C, et al. Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: a study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr 2006;7:22-30
   PubMed Web of Science ®Google Scholar
• Bellavia D, Pellikka PA, Abraham TP, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008;101:1039-45
   PubMed Web of Science ®Google Scholar
• Migrino RQ, Mareedu RK, Eastwood D, et al. Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr 2009;22:1396-402
   PubMedGoogle Scholar
• Kristen AV, Perz JB, Schonland SO, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007;9:617-24
   PubMed Web of Science ®Google Scholar
• Austin BA, Duffy B, Tan C, et al. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009;103:1429-33
   PubMed Web of Science ®Google Scholar
• Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation 2014;129:1840-9
   PubMed Web of Science ®Google Scholar
• Ogiwara F, Koyama J, Ikeda S, et al. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol 2005;95:538-40
   PubMed Web of Science ®Google Scholar
• Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 2013;6:1066-72
   PubMed Web of Science ®Google Scholar
• Han S, Chong V, Murray T, et al. Preliminary experience of 99mTc-Aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007;79:494-500
   PubMed Web of Science ®Google Scholar
• Janssen S, van Rijswijk MH, Piers DA, et al. Soft-tissue uptake of 99mTc-diphosphonate in systemic AL amyloidosis. Eur J Nucl Med 1984;9:538-41
   PubMedGoogle Scholar
• Glaudemans AW, van Rheenen RW, van den Berg MP, et al. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 2014;21:35-44
   PubMed Web of Science ®Google Scholar
• Kristen AV, Haufe S, Schonland SO, et al. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int J Cardiol 2013;164:179-84
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovascular Imaging 2011;4:659-70
   PubMed Web of Science ®Google Scholar
• Bokhari S, Castano A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195-201
   PubMed Web of Science ®Google Scholar
• de Haro-del Moral FJ, Sanchez-Lajusticia A, Gomez-Bueno M, et al. Role of cardiac scintigraphy with (9)(9)mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol (Engl) 2012;65:440-6
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470-8
   PubMed Web of Science ®Google Scholar
• Bokhari S, Shahzad R, Castano A, et al. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol 2014;21:175-84
   PubMed Web of Science ®Google Scholar
• Tanaka M, Hongo M, Kinoshita O, et al. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J Am Coll Cardiol 1997;29:168-74
   PubMed Web of Science ®Google Scholar
• Delahaye N, Dinanian S, Slama MS, et al. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur J Nucl Med 1999;26:416-24
   PubMedGoogle Scholar
• Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54:213-20
   PubMed Web of Science ®Google Scholar
• Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 2014;41:1652-62
   PubMed Web of Science ®Google Scholar
• Ruberg FL. T1 mapping in cardiac amyloidosis: can we get there from here? JACC Cardiovascular Imaging 2013;6:498-500
   Google Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93
   PubMed Web of Science ®Google Scholar
• Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92:343-9
   PubMed Web of Science ®Google Scholar
• Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51:1022-30
   PubMed Web of Science ®Google Scholar
• Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovascular Imaging 2009;2:1369-77
   PubMed Web of Science ®Google Scholar
• Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovascular Imaging 2010;3:155-64
   PubMed Web of Science ®Google Scholar
• Di Bella G, Minutoli F, Mazzeo A, et al. MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy. AJR Am J Roentgenol 2010;195:W394-9
   PubMed Web of Science ®Google Scholar
• Dungu JN, Valencia O, Pinney JH, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovascular Imaging 2014;7:133-42
   PubMed Web of Science ®Google Scholar
• Brooks J, Kramer CM, Salerno M. Markedly increased volume of distribution of gadolinium in cardiac amyloidosis demonstrated by T1 mapping. J Magn Res Imaging 2013;38:1591-5
   Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovascular Imaging 2013;6:488-97
   PubMed Web of Science ®Google Scholar
• White JA, Kim HW, Shah D, et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovascular Imaging 2014;7:143-56
   PubMed Web of Science ®Google Scholar
• Aquaro GD, Pugliese NR, Perfetto F, et al. Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis. Int J Cardiovasc Imaging 2014;30:1105-15
   Google Scholar
• APOLLO: the study of an investigational drug, patisiran (ALN-TTR02), for the treatment of transthyretin (TTR)-mediated amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT01960348
   Google Scholar
• A extension study to evaluate revusiran (ALN-TTRSC) in patients with transthyretin (TTR) cardiac amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT02292186
   Google Scholar
• Efficacy and safety of ISIS-TTR Rx in familial amyloid polyneuropathy. Available from: www.clinicaltrials.gov/ct2/show/NCT01737398
   Google Scholar
• Safety and efficacy evaluation of Fx-1006A in subjects with transthyretin amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT00925002
   Google Scholar
• Safety and efficacy of tafamidis in patients with transthyretin cardiomyopathy (ATTR-ACT). Available from: www.clinicaltrials.gov/ct2/show/NCT01994889
   Google Scholar
• The effect of diflunisal on familial transthyretin amyloidosis (DFNS01). Available from: www.clinicaltrials.gov/ct2/show/NCT01432587
   Google Scholar
• Phase I/2, open label, dose escalation study of NEOD001 in subjects with light chain (AL) amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT01707264
   Google Scholar
• The vital amyloidosis study, a Phase III, multicenter efficacy and safety study of NEOD001. Available from: www.clinicaltrials.gov/ct2/show/NCT02312206
   Google Scholar
• A study to evaluate the safety of GSK2398852 when co-administered with GSK2315698 in patients with systemic amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT01777243
   Google Scholar
• Study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT02245867
   Google Scholar
• Oral doxycycline administered as an adjunct to plasma cell directed therapy in light chain amyloidosis. Available from: www.clinicaltrials.gov/ct2/show/NCT02207556
   Google Scholar
• Epigallocatechin gallate (EGCG) in cardiac AL amyloidosis (EpiCardiAL). Available from: www.clinicaltrials.gov/ct2/show/NCT01511263
   Google Scholar
• A trial for the treatment of cardiac AL-amyloidosis with the green tea compound epigallocatechin-3-gallate (TAME-AL). Available from: www.clinicaltrials.gov/ct2/show/NCT02015312
   Google Scholar
• Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015;12(2):91-102
   Google Scholar